Lonza– tag –
-
Lonza Unveils Enhanced DNA-to-IND Biologics Manufacturing Offering with 6-Month Timelines, Introducing GS Ori-Go™
PharmaSource Switzerland Overview Lonza has announced an enhanced 'DNA-to-IND' offering for biologics, aiming to achieve IND-readiness for monoclonal antibody programs in as little as six months. This accelerated timeline is supported by... -
Lonza, Samsung Biologics, and Catalent Lead 2026 Biologics CDMO Market, Driven by AI Manufacturing & APAC Expansion
Towards Healthcare Unknown Overview Lonza, Samsung Biologics, and Catalent are identified as key players leading the 2026 biologics CDMO market. Lonza excels in end-to-end multi-modality and scientific innovation, Samsung Biologics in la... -
Global Biomanufacturing Leaders Lonza, Fujifilm Diosynth, AGC Biologics Expand CGT & mRNA Capacities
Healthcare Ranking USA Overview Major CDMOs including Lonza, Fujifilm Diosynth Biotechnologies, and AGC Biologics are aggressively expanding global manufacturing capacities for biologics, cell & gene therapies (CGT), and mRNA product... -
Lonza Significantly Expands Biologics Manufacturing Capacity by Over 200,000 Liters with New Swiss Facility
Lonza Press Release Switzerland Overview Lonza announced the operational launch of a state-of-the-art new facility in Visp, Switzerland, significantly expanding its biopharmaceutical manufacturing capabilities. This expansion adds over 2... -
Top 20 Biomanufacturing and CDMO Providers for 2026: Driving Innovation in Biopharma Production
Healthcare Ranking USA Overview The 2026 ranking of top biomanufacturing and Contract Development and Manufacturing Organization (CDMO) providers highlights industry leaders such as Lonza, Samsung Biologics, WuXi Biologics, and Thermo Fi... -
European Biotechs Drive Next-Gen Cell & Gene Therapy Manufacturing Innovation
BioSpace UK Overview European biotechnology firms are making significant strides in cell and gene therapy (CGT) manufacturing, focusing on scalability and automation. UK-based Oxford Biomedica, a leading viral vector CDMO, specializes in... -
Lonza Completes Pure-Play CDMO Transition, Reports Strong Q1 2026 Driven by Robust Demand
TipRanks.com USA Overview Lonza announced strong Q1 2026 results, propelled by robust demand for its CDMO services, and completed the divestment of its Capsules & Health Ingredients division. This strategic move cements Lonza's posit... -
Lonza Reports Strong Q1 2026 Performance, Driven by Robust CDMO Growth and Strategic Transformation into Pure-Play Biopharma Partner
Lonza Switzerland Overview Lonza delivered strong Q1 2026 performance across its Contract Development and Manufacturing Organization (CDMO) business, aligning with full-year expectations despite macroeconomic challenges. The company secu...
